Where to buy capmatinib
Capmatinib, sold under the brand name Tabrecta, is an anticancer drug used to treat metastatic non-small cell lung cancer in tumors with mutations that cause exon 14 of the MET gene encoding the membrane receptor HGFR to be skipped. Capmatinib was approved for medical use in the United States in May 2020 and is the first therapy approved by the U.S. Food and Drug Administration (FDA) to treat cancers with specific mutations (mutations that cause mesenchymal-epithelial metastasis or MET exon 14 skipping).
Non-small cell lung cancer is a disease in which malignant cancer cells form in lung tissue. It is the most common type of cancer, with up to 90% of lung cancers belonging to the non-small cell category. Mutations causing MET exon 14 skipping are found in 3-4% of cancer patients. The drug inhibits c-Met, a tyrosine kinase that plays a role in embryonic development, organogenesis and wound healing, but also plays a role in the development of cancer. The most common adverse reactions were peripheral edema, nausea, fatigue, vomiting, dyspnea, and decreased appetite.

The original drug capmatinib has only recently been approved for marketing in China. Therefore, its price and medical insurance-related information are not yet known. Domestic hospitals or pharmacies cannot yet purchase this drug. In Hong Kong, each box of the original capmatinib in 200 mg 60 specifications sells for more than 30,000 yuan. Overseas, the price of each box of the European version of the original drug in 200 mg and 120 doses is as high as more than 50,000 yuan. Although the price may fluctuate due to exchange rates, it is obviously quite expensive.
However, there are also lower-priced generic capmatinib drugs available in overseas markets. These drugs are similar in ingredients to the original drug. For example, a drug produced by a pharmaceutical factory in Laos is 200mg*56 tablets. The price per box is only more than 3,000 yuan, although the price may also change due to exchange rate fluctuations. For more information on overseas drug prices and related information, please consult Yaode Medical Consultants.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)